To get a sense of who is truly in control of Bristol-Myers Squibb Company (NYSE:BMY), it is important to understand the ...

Bristol Myers Squibb said on Friday its blockbuster drug Reblozyl in combination with another therapy failed to meet the main ...

The companies’ new effort would bypass traditional middlemen to cut the drug’s monthly cost from a list price of around $606 ...

Bristol Myers Squibb Co. closed 26.69% short of its 52-week high of $63.33, which the company achieved on March 11th.

The joint venture is launching a direct-to-consumer service of Eliquis after discussions with the Trump administration.

The program is the latest example of pharmaceutical companies bypassing traditional drug distribution channels for people who ...

Pharmaceutical giants introduce an insurance-free pathway for top anticoagulant Eliquis, following similar direct-to-patient ...

Bristol-Myers Squibb’s shares (currently trading at $46.80) have posted a disappointing 18% loss, well below the S&P 500’s ...

Sotyktu (deucravacitinib) has been assigned a Prescription Drug User Fee Act (PDUFA) goal date of March 6, 2026.

We recently published 8 Stocks That Jim Cramer Recently Talked About. Bristol-Myers Squibb Company (NYSE:BMY) is one of the stocks Jim Cramer recently discussed. Bristol-Myers Squibb Company (NYSE:BMY ...

This was the stock's second consecutive day of losses.

US FDA accepts Bristol Myers Squibb’s sNDA for Sotyktu to treat adults with active psoriatic arthritis: Princeton, New Jersey Tuesday, July 22, 2025, 12:00 Hrs [IST] Bristol Mye ...